Evidence map›Paper›PMID 39035880›Full record

ArticleACS omega2024

Nitroreductase-Responsive Fluorescent "Off-On" Photosensitizer for Hypoxic Tumor Imaging and Dual-Modal Therapy.

Dan Shen, Shangli Ding, Quan Lu, Zhengjun Chen, Ling Chen, Jiajia Lv, Jie Gao, Zeli Yuan

Abstract read
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dan ShenCollege of Pharmacy, Zunyi Medical University, Zunyi, Guizhou 563003, China.
Shangli DingCollege of Pharmacy, Zunyi Medical University, Zunyi, Guizhou 563003, China.
Quan LuCollege of Pharmacy, Zunyi Medical University, Zunyi, Guizhou 563003, China.
Zhengjun ChenCollege of Pharmacy, Zunyi Medical University, Zunyi, Guizhou 563003, China.
Ling ChenCollege of Pharmacy, Zunyi Medical University, Zunyi, Guizhou 563003, China.
Jiajia LvCollege of Pharmacy, Zunyi Medical University, Zunyi, Guizhou 563003, China.
Jie GaoCollege of Pharmacy, Zunyi Medical University, Zunyi, Guizhou 563003, China.ORCID https://orcid.org/0000-0002-6143-6284
Zeli YuanCollege of Pharmacy, Zunyi Medical University, Zunyi, Guizhou 563003, China.ORCID https://orcid.org/0000-0001-5354-769X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Photothermal therapy synergized with photodynamic therapy for the treatment of tumors has emerged as a promising strategy. However, designing photosensitizers with both high photothermal efficiency and high photodynamic performance remains challenging. In contrast, the strategy of rationalizing the design of photosensitizers using the physiological properties of tumors to improve the photon utilization of photosensitizers during phototherapy is more advantageous than the approach of endowing a single photosensitizer with complex functions. Herein, we propose a molecular design (CyNP) to convert from photothermal therapy to photodynamic synergistic photothermal therapy based on the prevalent properties of hypoxic tumors. In the normoxic region of tumors, the deactivation pathway of CyNP excited state is mainly the conversion of photon energy to thermal energy; in the hypoxic region of tumors, CyNP is reduced to CyNH by nitroreductase, and the deactivation pathway mainly includes radiation leap, energy transfer between CyNP and oxygen, and conversion of photons energy to heat energy. This strategy enables real-time fluorescence detection of hypoxic tumors, and it also provides dual-mode treatment for photothermal and photodynamic therapy of tumors, achieving good therapeutic effects in vivo tumor treatment. Our study achieves more efficient tumor photoablation and provides a reference for the design ideas of smart photosensitizers.

Identifiers

PMID39035880
PMCPMC11256082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.